Pure red cell aplasia associated with myelodysplastic syndromes TO 
THE EDITOR
Myelodysplastic syndromes are clonal hematopoietic diseases characterized by pancytopenia, dysplastic hematopoiesis, and a high number of abnormal erythroid precursors in the marrow. However, a minority have a very few (less than 5%) or absence of erythroid precursors, or a blockage of erythroid lineage to pronormoblasts, whereas the other lineages keep their dysplastic characteristics. This novel entity is called SMD associated with PRCA. In a large series of 360 patients with MDS, 1.6% of them were found to have a PRCA. 1 Only 16 cases in the literature have been described. 2 We report here six more patients with different clinical, cytogenetical and prognostic features.
Six patients presented a rapid aggravation of macrocytic anaemia with low reticulocyte response (reticulocyte count Ͻ1%) during the evolution of MDS corresponding to PRCA. These six cases of PRCA represent 4% of all myelodysplastic syndromes over 3 years in our unit. There were five females and one male and the median age was 73.3 years (range 52 to 91), as shown in Table 1 . Onset of pure red cell aplasia was observed with a mean of 28 months (range 8 to 60 months). All these patients had been profoundly anemic for at least 1 month. Other causes of macrocytic anemia with low count of reticulocytes were excluded. Karyotypes at diagnostic showed in 5q 13q33 two patients deletion and 5q14q34 deletion in two patients. The others were normal. Polyclonal hypergammaglobulinemia was observed in three patients. Antinuclear antibodies, and latex-Waaler rose test were negative. Three patients had a parvovirus B19 serology IgG positive, and two had PCR positive in sera.
All patients had myelodysplastic feature on medullar aspirate. There were five RAEB and one RARS. In RAEB, the median percentage of blasts was 7.6% (range 6 to 9%). At onset, erythroid lineage represented a mean percentage of 21%. The erythroid cells were drasti- All patients received transfusions of red blood cell packages at a median interval of 1 month, which increased to one transfusion every 2 or 3 weeks when erythroblastopenia occurred. The two patients who were B19 PCR-positive received 1 g/kg of body weight of polyvalent immunoglobulins for 2 days. However, none responded and persistent erythroblastopenia was observed. One patient received amifostine for 6 months with a dose of 300 mg three times a week but she did not improve.
Of the six patients, three have died because of blastic transformation, sepsis or unrelated cause between 4 and 12 months after the diagnosis of PRCA.
We stress the difficulty of diagnosing PRCA within myelodysplastic disorders where megakaryocytes and granulocytes counts can be elevated. Two to 5% maximum of erythroblasts were described in some studies, but this can be uninterpretable if there is other lineage proliferation or hypoplastic MDS. Our patients presented with rich medullar aspirate and no increased blastic infiltration excepting in one patient who evolved into RAEB-t. In this case the number of platelets and leukocytes was stable for 5 months before transformation, so it was unlikely that PRCA was secondary to a medullar invasion of blasts.
At onset, no erythroblastopenia was present in the initial medullar aspirate. In these patients, only erythroid lineage fell, without evolution of leukocytes and platelets. There was only one blastic evolution from an initial RAEB.
Four patients out of six PRCA had 5q− syndrome. These two entities are not synonymous because 5q− syndrome can be associated with a normal, decreased or increased number of erythroid precursors in bone marrow. 3 Two patients had a parvovirus B19 PCR positive. In our study, serology IgG was positive for three cases and PCR positive for two cases Leukemia out of four. Absence of IgM can be explained by the fact that infection by parvovirus B19 goes back at least 1 month before PRCA is discovered on medullar aspirate. Immunodepression favors chronic infection by parvovirus B19, as there are no neutralizing antibodies to eliminate the virus. The absence of response to intravenous immunoglobulins correlates with the fact that B19 PCR positive patients also had the del 5q, which would be a negative factor of response to immunosuppressive therapy according to Lacy et al. 4 PRCA could be a consequence of extreme apoptosis of the red cell progenitors leading to their total destruction. Programmed cell death is maximal in advanced RA, RARS, and RAEB. This correlates with our findings that erythroblastopenia was diagnosed only in MDS with less than 10% of blasts. Excessive cell death could be due to cytokines like TNF-␣. The EPO action is related to its anti-apoptotic action and has been reported to be efficient in PRCA with myelodysplasia that did not respond to corticotherapy. 2 Amifostine has been tried for only one patient without effect, as a mitogenic agent in myelodysplastic syndrome, protecting stem cells against exaggerated apoptosis. However, a study did not confirm the results of List AF et al, 5 with a low level of response to this phosphorylated thiolamine. 6 The association of PRCA with lymphoproliferative disorders and a good response to immunosuppressive therapy point to the fact that erythroblastopenia can be mediated by an autoimmune T cell subset. In vitro inhibition of erythropoiesis in marrow culture systems from patients with PRCA by T cells was demonstrated by Abkhowitz et al. 7 A recent study has reported a good erythroid response under cyclosporin A and antithymocyte globulin in hypoplastic myelodysplastic syndrome. 
